CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma

May 12th 2025

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma

April 24th 2025

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Dr Ahmed on the Safety Profile of NKTR-255 in Relapsed/Refractory LBCL

April 23rd 2025

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL

April 23rd 2025

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Dr Ip on Reasons for Studying Real-World CAR T-Cell Therapy Outcomes in LBCL

April 21st 2025

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Dr Bishop on the Rationale for Evaluating Anito-Cel in R/R Myeloma

April 21st 2025

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Dr Choi on the Importance of Education on CAR T-Cell Therapy Manufacturing in Hematologic Malignancies

April 21st 2025

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

April 18th 2025

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

LV20.19 CAR T-Cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL

April 18th 2025

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Dasatinib Plus CAR T-Cell Therapy Shows Efficacy in Ph+ Acute Lymphoblastic Leukemia

April 17th 2025

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Responses With Compassionate Use of MDC-CAR-BCMA001 Support Further Study in R/R Myeloma and AL Amyloidosis

April 17th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Dr Farid on the Rationale for Evaluating MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 16th 2025

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Dr Choi on Advances With Cell Therapy in Hematologic Malignancies

April 14th 2025

Yeong “Christopher” Choi, PhD, MBA, discusses the importance of developing biomedical technologies for hematologic malignancies and other diseases.

Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma

April 12th 2025

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma

April 11th 2025

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

CAR T-Cell Therapy for Solid Tumors: Leveraging Lessons From Hematologic Malignancies

April 9th 2025

As we plan for a future with solid tumor CAR T-cell therapy, we should be mindful of lessons learned from CAR T-cell agents for hematologic malignancies.

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

April 8th 2025

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.